Research Triangle Park, NC (PRWEB) October 23, 2015
Muses Labs (http://museslabs.com), an Alzheimer’s disease digital health company, will present at the upcoming Cleveland Clinic Medical Innovation Summit 2015, which this year is focused on the fast moving field of neurosciences with the theme of “Memory. Mood. Movement.”
Muses Labs’ CEO, Vik Chandra, is scheduled to speak on Tuesday, October 27 in a session titled “The New Role of Biomarkers and Big Data in Brain Health” at the Innovation Summit.
The latest Alzheimer’s research in epidemiology, lifestyle, and disease comorbidity supports the observation that multiple interventions can reduce and delay the onset of Alzheimer’s disease dramatically. Policy makers are urging the Alzheimer’s field to put more emphasis on these disease treatment approaches.
Muses Labs offers a big-data enabled technology that helps physicians use a combination approach with their patients to address the multiple underlying pathophysiology of Alzheimer’s disease in a personalized manner. Muses Labs' offerings also support individuals and their caregivers through the treatment process to improve ease of use and outcomes.
Alzheimer's disease is a chronic disease with multiple underlying medical causes. It is widely acknowledged that it will not be address by a single medication, but possibly by a broad-based personalized therapy. The Muses Labs MEND™ Protocol utilizes the patient’s diagnostic status, genetic profile, blood chemistry, nutritional and metabolic tests, and family medical history to recommend a personalized combination of lifestyle, cognition interventions, pharmacological and non-pharmacological interventions. Its aim is to deliver far better patient outcomes than current Alzheimer’s medications.
Those interested in more information can contact Muses Labs at http://www.museslabs.com.